Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Leukine for autoimmune pulmonary alveolar proteinosis
ISRCTN18931678Phase 2Completed
- Sponsor
- Niigata University Medical and Dental Hospital
- Start
- Jul 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sargramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Niigata University Medical and Dental Hospital. Primary endpoints: Improvement in oxygenation, Change in A-aDO2 over untreated observation period versus induction treatment period and 1 more. Started Jul 2005; status: completed.
02
Drugs
sargramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on ISRCTN18931678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18931678.